Polymer-free stents no better than durable-polymer stents in long run
Germany: Polymer-free versus durable polymer drug-eluting stent (DES) yielded no measurable differences at 10 years in patients with coronary artery disease (CAD), show results from ISAR-TEST-5 trial. The study, published in the Journal of the American College of Cardiology, found the incidence of stent thrombosis to be low and comparable in both the groups. Also, long-term adverse outcomes were similar for both groups.
There is a limited outcome data after extended long-term follow-up of patients with coronary artery disease treated with drug-eluting stents (DES) in CAD patients treated with DES in randomized clinical trials. Stenting done with polymer-free or durable polymer DES may yield performance differences that may emerge over time. Sebastian Kufner, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany, and colleagues assessed the 10-year outcomes of patients enrolled in the ISAR-TEST-5 (Test Efficacy of Sirolimus- and Probucol-Eluting Versus Zotarolimus-Eluting Stents) trial.
3,002 patients (median age 67.8 years) were randomized to treatment with either polymer-free sirolimus- and probucol-eluting stents (n = 2,002) or durable polymer zotarolimus-eluting stents (n = 1,000)
The primary endpoint was the composite of cardiac death, target vessel-related myocardial infarction, or target lesion revascularization (a device-oriented composite endpoint [DOCE]).
Key findings of the study include:
- At 10 years, 63.9% of patients were alive.
- The rates of DOCE and POCE were high in both groups with no difference in the incidence between polymer-free sirolimus- and probucol-eluting stents and durable polymer zotarolimus-eluting stents (DOCE: 43.8% vs. 43.0%, respectively; hazard ratio: 1.01; POCE: 66.2% vs. 67.7%, respectively; hazard ratio: 0.94).
- The rates of the individual components of the composite endpoints were comparable in both groups.
- The incidence of definite/probable stent thrombosis over 10 years was low and comparable in both groups (1.6% vs. 1.9%; hazard ratio: 0.85).
"At 10 years, there were no measurable differences in outcomes between patients treated with polymer-free versus durable polymer DES. The incidence of stent thrombosis was low and comparable in both groups. High overall adverse clinical event rates were observed during extended follow-up," concluded the authors.
The study, "10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents," was published in the Journal of the American College of Cardiology.
DOI: 10.1016/j.jacc.2020.05.026
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.